SCHEMBL21592302

SCHEMBL21592302

COc1cc(CN(CCCc2cncnc2)Cc2cn(C)c3ccccc3c2=O)ccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 7/20 0.39
▸ KCNJ5 P48544 3/20 0.35
▸ KCNJ3 P48549 3/20 0.35
▸ USP2 O75604 3/20 0.35
▸ CYP1A2 P05177 3/20 0.35
▸ CYP3A4 P08684 3/20 0.35
▸ CYP2C9 P11712 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ CASP1 P29466 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ PLA2G7 Q13093 1/20 0.34
▸ HBB P68871 1/20 0.34
▸ CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21592261 0.90 KCNA5 (0.38) KCNA5KCNJ5KCNJ3USP2CYP1A2
SCHEMBL21592260 0.87 LOX (0.38) KCNA5KDM4ETP53GSK3BHTR5A
SCHEMBL21591542 0.85 LTA4H (0.35) KCNA5KCNJ5KCNJ3USP2CYP1A2
SCHEMBL21592290 0.85 CYP1A2 (0.39) KCNA5KCNJ5KCNJ3USP2CYP1A2
SCHEMBL21592259 0.84 IDH1 (0.41) TSHRALDH1A1MAPK1GSK3B
SCHEMBL21591465 0.83 HTR5A (0.32) KCNA5ALDH1A1KDM4ETP53GSK3A
SCHEMBL21591563 0.83 SMN1; SMN2 (0.37) MEN1LMNATSHRKMT2AALDH1A1
SCHEMBL21592296 0.81 KCNA5 (0.47) KCNA5KCNJ5KCNJ3
SCHEMBL21592262 0.81 KDM4E (0.34) KCNA5MEN1LMNAKMT2AALDH1A1
SCHEMBL21591492 0.81 KCNA5 (0.46) KCNA5KCNJ5KCNJ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS KCNA5 2592/4885KCNJ5 1509/4885KCNJ3 1776/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS KCNA5 2592/4885KCNJ5 1509/4885KCNJ3 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback